
associated with hypersecretion of IL6 or interferons, in particular rheumatoid arthritis, by administering the compound as described herein according to Formula I.

[0024] Accordingly, in a first aspect as described herein, a compound as described herein is provided for use in medicine having a Formula I:




I

[0025] The compound according to Formula I, surprisingly, exhibits *in vivo* in human a very different profile from other animal species, which contrasts with *in vitro* predictions. Indeed, *in vivo* it has been demonstrated that in human, the apparent terminal half life of the compound according to Formula I is significantly longer than in the other animal species by at least 3 fold. This causes accumulation in human resulting in a maintained therapeutic effect over an extended period of time, thereby allowing once daily to once weekly dosing. Thus the compound according to Formula I may provide advantages including a low frequency dosage regimen and / or increased patient compliance. In particular, the impact of non adherence, if the patient misses a dose, might be reduced.

[0026] In a particular aspect, the compound according to Formula I is provided for use in the prophylaxis and / or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, in particular rheumatoid arthritis.

[0027] In a further aspect, the present disclosure provides pharmaceutical compositions comprising the compound of the invention according to Formula I, and a pharmaceutical carrier, excipient or diluent, which additionally comprises an additional therapeutic agent wherein the additional therapeutic agent is according to Formula II:




II

In a particular aspect, the pharmaceutical composition may additionally comprise further therapeutically active ingredients suitable for use in combination with the compound according to Formula I. In a more particular aspect, the further therapeutically active ingredient is a compound for the treatment of arthritis. In a most particular aspect, the further therapeutically active ingredient is a compound for the treatment of rheumatoid arthritis.

[0028] Moreover, the compound according to Formula I, useful in the pharmaceutical compositions and treatment methods disclosed herein, is pharmaceutically acceptable as prepared and used.

CLAIMS


1. A compound according to Formula I:



I

or a pharmaceutically acceptable salt thereof, or a solvate or a pharmaceutically acceptable salt of a solvate, for use in medicine.

2. A compound according to Formula I:




I

or a pharmaceutically acceptable salt thereof, or a solvate or a pharmaceutically acceptable salt of a solvate, for use in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

3. The compound according to claim 2 for use in the treatment of rheumatoid arthritis.
4. The compound according to claim 2 for use in the treatment of inflammatory bowel diseases.
5. The compound according to claim 2 for use in the treatment of psoriasis and/or psoriatic arthritis.
6. The compound for use according to any one of claims 1-5, in combination with another therapeutic agent.
7. The compound for use according to claim 6, wherein the further therapeutic agent is a rheumatoid arthritis treating agent.


8. A pharmaceutical composition, comprising a compound according to Formula I:



I

and a pharmaceutically acceptable carrier, excipient or diluent.


9. The pharmaceutical composition according to claim 8, which additionally comprises an additional therapeutic agent.
10. The pharmaceutical composition according to claim 9, wherein said additional therapeutic agent is a rheumatoid arthritis treating agent.
11. The pharmaceutical composition according to claim 9, wherein the additional therapeutic agent is according to Formula II:



II

12. The pharmaceutical composition according to claim 11, wherein the ratio of Formula I/Formula II is from 1/5 to 1/20.
13. The pharmaceutical composition according to claim 11, wherein the ratio of Formula I/Formula II is from 1/5 to 1/10.
14. The pharmaceutical composition according to any one of claims 8-13, for use in medicine.
15. The pharmaceutical composition according to any one of claims 8-13, for use in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
16. The pharmaceutical composition according to any one of claims 8-13, for use in the treatment of rheumatoid arthritis.

17. The pharmaceutical composition according to any one of claims 8-13, for use in the treatment of inflammatory bowel diseases.
18. The pharmaceutical composition according to any one of claims 8-13, for use in the treatment of psoriasis and/or psoriatic arthritis.
19. Use of a therapeutically effective amount of a compound of claims 1-7, or the pharmaceutical composition of claims 8-13 in the manufacture of a medicament for the prophylaxis and/or treatment of a mammal susceptible to or afflicted with a condition selected from inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, more particularly rheumatoid arthritis , wherein said compounds, JAK inhibitor and said pharmaceutical composition exhibit demonstrable activity *in vivo*.
20. The use according to claim 19, wherein the said compounds, JAK inhibitor and said pharmaceutical composition are to be administered in combination with one or more additional therapeutic agents.
21. The use according to claim 20, wherein said additional therapeutic agent is a rheumatoid arthritis treating agent.
22. The use according to claim 20, wherein the additional therapeutic agent is according to Formula II:




II .

23. The use according to claim 22, wherein the ratio of Formula I/Formula II is from 1/5 to 1/20.
24. The use according to claim 22, wherein the ratio of Formula I/Formula II is from 1/5 to 1/10.
25. The use according to any of claims 19-24, wherein the mammal is a human.

CLAIMS


1. A compound according to Formula I:



I

or a pharmaceutically acceptable salt thereof, or a solvate or a pharmaceutically acceptable salt of a solvate, for use in medicine.

2. A compound according to Formula I:




I

or a pharmaceutically acceptable salt thereof, or a solvate or a pharmaceutically acceptable salt of a solvate, for use in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.


3. The compound according to claim 2 for use in the treatment of rheumatoid arthritis.
4. The compound according to claim 2 for use in the treatment of inflammatory bowel diseases.
5. The compound according to claim 2 for use in the treatment of psoriasis and/or psoriatic arthritis.
6. The compound for use according to any one of claims 1-5, in combination with another therapeutic agent.
7. The compound for use according to claim 6, wherein the further therapeutic agent is a rheumatoid arthritis treating agent.

8. A pharmaceutical composition, comprising a compound according to Formula I:



I


and a pharmaceutically acceptable carrier, excipient or diluent, which additionally comprises an additional therapeutic agent wherein the additional therapeutic agent is according to Formula II:



II

9. The pharmaceutical composition according to claim 8, wherein the ratio of Formula I/Formula II is from 1/5 to 1/20.
10. The pharmaceutical composition according to claim 8, wherein the ratio of Formula I/Formula II is from 1/5 to 1/10.
11. The pharmaceutical composition according to any one of claims 8-10, for use in medicine.
12. The pharmaceutical composition according to any one of claims 8-10, for use in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.
13. The pharmaceutical composition according to any one of claims 8-10, for use in the treatment of rheumatoid arthritis.
14. The pharmaceutical composition according to any one of claims 8-10, for use in the treatment of inflammatory bowel diseases.
15. The pharmaceutical composition according to any one of claims 8-10, for use in the treatment of psoriasis and/or psoriatic arthritis.

16. Use of a therapeutically effective amount of a compound of claims 1-7, or the pharmaceutical composition of claims 8-10 in the manufacture of a medicament for the prophylaxis and/or treatment of a mammal susceptible to or afflicted with a condition selected from inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, more particularly rheumatoid arthritis , wherein said compounds, JAK inhibitor and said pharmaceutical composition exhibit demonstrable activity *in vivo*.
17. The use according to claim 16, wherein the said compounds, JAK inhibitor and said pharmaceutical composition are to be administered in combination with one or more additional therapeutic agents.
18. The use according to claim 17, wherein said additional therapeutic agent is a rheumatoid arthritis treating agent.
19. The use according to claim 17, wherein the additional therapeutic agent is according to Formula II:



II .

20. The use according to claim 19, wherein the ratio of Formula I/Formula II is from 1/5 to 1/20.
21. The use according to claim 19, wherein the ratio of Formula I/Formula II is from 1/5 to 1/10.
22. The use according to any of claims 16-21, wherein the mammal is a human.